Hepatocellular carcinoma (HCC) is one of the most common lethal human malignancies
worldwide. Sorafenib is the first‐line drug approved by the United States Food and Drug …

Abstract p21-Activated kinase 5 (PAK5) is the last identified member of the PAK family. The
PAKs are highly conserved serine/threonine and effector proteins for Cdc42 and Rac and …

Background: Sorafenib (Nexavar®) is an FDA-approved systemic therapy for advanced
hepatocellular carcinoma (HCC). However, the low efficacy and adverse effects at high …

Background Sorafenib is an oral multi-kinase inhibitor that was approved by the US Food
and Drug Administration for the treatment of patients with advanced hepatocellular …

Objective To investigate the inhibitory effect of sorafenib in combination with cisplatin (DDP)
on the proliferation of hepatocellular carcinoma cells and explore the molecular …

The mechanisms of resistance to the targeted drug sorafenib in the treatment of
hepatocellular carcinoma (HCC) are poorly understood. The purpose of this study was to …

Multi-kinase inhibitor sorafenib represents a major breakthrough in the therapy of advanced
hepatocellular carcinoma (HCC). Amplified in breast cancer 1 (AIB1) is frequently …

Sorafenib is currently used as a standard treatment to suppress the progression of
hepatocellular carcinoma (HCC), especially in advanced stages. However, patients who …

Sorafenib is the standard first-line systemic drug for advanced hepatocellular carcinoma
(HCC), but it also induces the activation of Akt, which contributes to the mechanisms for the …

Sorafenib resistance is a classic problem related to the treatment of advanced
hepatocellular carcinoma (HCC). There is a recognized need to explore new drug …